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Background: Traditional Chinese medicines have been used for anti-asthma treatment for several centuries in
many Asian countries, and have been shown to effectively relieve symptoms. Our previous study demonstrated that
a complex traditional Chinese medicine (CTCM) administered in nebulized form through the intratracheal route is
effective against early-phase air-flow obstruction and can inhibit IL-5 production in ovalbumin (OVA)-sensitized
guinea pigs. However, the antiasthmatic mechanisms of CTCMs are still unclear.
Methods: In this study, we examined the underlying mechanism of a CTCM that we used in our previous study in
order to ascertain its function in the early-phase response to OVA challenge.
In each group, 10–12 unsensitized or OVA-sensitized guinea pigs were treated with nebulized CTCM before OVA
challenge, and the airway responses of the animals to OVA were recorded. Bronchoalveolar lavage fluid (BALF)
samples were collected 5 min after OVA challenge, and the histamine and IL-4 contents in the BALF were
measured. P815 cells (a mouse mast cell line) were untreated or pretreated with CTCM or cromolyn sodium
(a mast cell stabilizer), and incubated with Compound 48/80 (mast cell activator) for 9 hr. The levels of histamine
and IL-4 released from the cells were quantified.
Results: We found that the inhibition of bronchoconstriction by the CTCM was attenuated by pretreatment with
propranolol, suggesting that the CTCM has a bronchodilator effect that is associated with beta-adrenergic receptor.
Our results also showed that the CTCM inhibited histamine and IL-4 secretion in the OVA-induced airway
hypersensitivity in guinea pigs at 5 min post-OVA challenge, and in vitro study revealed that the CTCM is able to
stabilize mast cells.
Conclusion: In conclusion, our results suggested that the CTCM is a kind of bronchodilator and also a mast cell
stabilizer. Our findings provide useful information regarding the possible mechanism of the CTCM, and show its
potential for application in the treatment of allergenic airway disease.
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Asthma is a complex syndrome with multiple causes, which
include biological and environmental factors. Airway in-
flammation plays a key role in the onset of allergic asthma.
The inflammation response is characterized by dual re-
sponses (early- and late-phase responses to allergen inhal-
ation), acute and transient airway hyperresponsiveness
(AHR) and infiltration of inflammatory cells (mast cells,
lymphocytes, and eosinophils) into the airways [1-6]. Cur-
rently, inhaled corticosteroids with or without long-acting β
agonists are the mainstay of treatment for asthma. How-
ever, large proportions of patients are poorly-controlled
with this type of management. Anti-leukotrienes are cur-
rently used in therapy, but are less effective than inhaled
corticosteroids [7].
In chronic inflammatory disorder of the airways, many
cell types are involved, including eosinophils, lymphocytes,
macrophages, neutrophils and mast cells. Of these, eosino-
phils are the most characteristic cell type that has been
shown to be correlated with the severity of asthma [8], as
several mediators resulting from eosinophil activation may
contribute to the contraction of the airway smooth mus-
cles [9,10]. In addition, mast cells have long been consid-
ered to play an important role in the pathophysiology of
asthma, as they release a variety of mediators, including
bronchoconstrictors (i.e., histamine, cysteinyl-leukotrienes
and prostaglandins D2) [11-13]. Mast cells are thought to
be a major source of IL-4 and other pro-inflammatory cy-
tokines [14], and the secretion of cytokines may act as a
trigger for the induction of subsequent persistent produc-
tion of IL-4 and IL-5 by lymphocytes [15,16]. Activation of
mast cells contributes to early-phase asthmatic responses
(EAR), which involve airway smooth muscle constriction,
vascular leakage, increased mucus production, enhanced
AHR and recruitment of inflammatory cells [17]. It is
well-established that cross-linking of IgE Abs on mast cells
by Ag triggers the release of mediators and cytokines,
which cause immediate allergic reactions [15,18-20].
Using animal models, studies have shown that several for-
mulas of complex traditional Chinese medicines (CTCMs)
could inhibit the EAR after stimulation of antigens [21-27].
These Chinese medicines are administered orally, and the
mechanisms of their effects remain unclear. In our previous
study, we demonstrated that a CTCM administered in ne-
bulized form through the intratracheal route was effective
against early-phase air-flow obstruction and inhibited IL-5
in bronchoalveolar lavage fluid (BALF) in ovalbumin
(OVA)-sensitized guinea pigs [28]. The mechanism of the
effect on asthmatic responses in sensitized guinea pigs
after treatment with a CTCM is still unclear. Whether
CTCMs stabilize mast cells and play a role in the relax-
ation of airway smooth muscle or the inhibition of airway
contraction needs to be investigated. In this study, we
used Compound 48/80 to activate mast cells, and thestabilization effect of a CTCM on mast cells was investi-
gated by measuring the release of histamine and IL-4 from
mast cells. In addition, the levels of histamine and IL-4 in
the BALF of OVA-sensitized guinea pigs that inhaled the
CTCM were analyzed. We used both in vivo and in vitro
models to investigate the mechanism underlying the thera-
peutic effect of the CTCM in asthma treatment.
Methods
Sensitization and challenge of animals
The protocol for the animal experiment was reviewed and
approved by the Animal Care and Use Committee of Na-
tional Cheng Kung University. Sensitization of guinea pigs
was performed as per the method described in our previ-
ous study [28]. Briefly, a total of 62 specific pathogen-free
Dunkin-Hartley male guinea pigs (400 ~ 600 g) were pur-
chased from the National Laboratory Animal Center
(Taipei, Taiwan), and the animals were actively IgE-
sensitized to OVA (grade VI; Sigma-Aldrich, St. Louis, MO,
USA). Briefly, on day one of sensitization, guinea pigs were
sensitized by intraperitoneal injection of OVA (100 μg with
10 mg of aluminum hydroxide [Al(OH)3] gel in 0.5 ml of
normal saline), and a booster sensitization (50 μg of OVA
and 5 mg of Al(OH)3 gel in 0.25 ml normal saline) was
performed on day 7. Then, the sensitized guinea pigs were
exposed to an aerosol of 1% OVA (w/v) in normal saline
for 20 sec on day 14 using a Pulmo-Aide compressor
(model 5650D; DeVilbiss, Somerset, PA, USA). For bron-
choalveolar lavage collection and measurement of airway
responses to OVA, the animals were anesthetized with ur-
ethane (2 g/kg i.p.), intubated, and challenged with 1%
OVA (w/v) for 20 sec with/without CTCM for 5 min by
nebulization on day 21. Unsensitized guinea pigs were
treated in the same way with normal saline. The detailed
treatment was as shown in Additional file 1: Figure S1A.
Preparation of the Chinese herbal formula
In general, the EAR reaches a peak at about 5–30 min after
challenge and lasts for around 2 hours, and the EAR is
followed by the late-phase asthmatic responses (LAR),
which occur 4–12 h after challenge and may last for several
hours or even few days [29]. In this study, a CTCM for-
mula similar to the xiao-qing-long-tang (XQLT) formula
that is used by traditional Chinese medical physicians for
the treatment of asthmatic patients was used. The XQLT
formula has been proven to suppress the EAR and LAR in
sensitized guinea pigs via oral administration [22]. The for-
mula includes eight Chinese herbs: Ephedrae herba (stem
of Ephedrae sinica Stapf, 18.75 g), Paeoniae radix (root of
Paeoniae lactiflora Pallas, 18.75 g), Glycyrrhizae radix (root
and rhizome of Glycyrrhiza uralensis Fischer, 18.75 g),
Cinnamonomi ramulus (cortex of Cinnamomum cassia
Blume, 18.75 g), Asari herba cum radice (whole plant of
Asarum sieboldii Miq, 18.75 g), bitter apricot seed (Prunus
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(leaves of Perilla frutescens (Labiatae), 18.75 g), and
Ledebouriella root (Saposhnikovia divaricate (Apiaceae),
18.75 g). The herbs were purchased from a government-
approved herbal company (Hong-Cheng Chinese Medicine,
Tainan, Taiwan). All dried herbs were dipped into 800 ml
distilled water for 30 min, then boiled and maintained at
about 103°C for 15 min. The resulting decoction was con-
centrated to approximately 350 ml, and was then cooled
and filtered through a 0.45-mm filter. The decoction was fi-
nally lyophilized to yield 21 g dried powder, which was
stored at 4°C. The dried extract was dissolved in saline be-
fore use.Experimental design and administration
Pulmonary resistance (RL) was measured before treatment
and challenge as the baseline control. Then, the RL was
recorded after challenge every 5 min for the first hour and
every 30 min during the following 5 hours. Bronchoalveo-
lar lavage was performed 6 hr after ovalbumin challenge.
The guinea pigs were randomly divided into six groups:
(1)NSGP_S (n = 10): unsensitized guinea pigs treated
with saline by nebulization;
(2)NSGP_M (n = 10): unsensitized guinea pigs treated
with 0.06 g/ml CTCM for 5 min by nebulization;
(3)SGP_O (n = 10): sensitized guinea pigs challenged
with OVA by nebulization;
(4)SGP_MO (n = 12): sensitized guinea pigs treated
with 0.06 g/ml nebulized CTCM for 5 min, followed
by OVA challenge by nebulization (at 5 min post-
CTCM nebulization);
(5)SGP_AMO (n = 12): sensitized guinea pigs pre-
treated with β-adrenoceptor antagonist propranolol
(1 mg/kg i.v.) for 3 min before treating with
nebulized 0.06 g/ml CTCM for 5 min, and finally
challenged by OVA by nebulization (at 5 min
post-CTCM);
(6)NSGP_O (n = 10): unsensitized guinea pigs
challenged with OVA by nebulization.
Measurement of airway responses to OVA challenge
On day 21, airway responses were measured according
to the method described by Abraham et al. [30]. Briefly,
guinea pigs were anesthetized with urethane (2 g/kg; i.p.).
A balloon catheter placed through one nostril into the end
of esophagus was used to measure pleural pressure; and
a catheter placed into the trachea was used to measure
lateral pressure (Additional file 1: Figure S1B). Trans-
pulmonary pressure was the difference between lateral
and pleural pressure. A pneumotachograph was connected
to the endotracheal tube, by which the signals of flow and
transpulmonary pressure were recorded on a computer.The pulmonary resistance (RL) calculated from the
transpulmonary pressure and flow at the isovolumetric
points.
Histamine and IL-4 in bronchoalveolar lavage fluid (BALF)
Bronchoalveolar lavage fluid (BALF) was collected 5 min
after challenge. The lung lavage was performed gently,
using 3 ml of PBS (phosphate-buffered saline) at 37°C.
The tracheal cannula was clamped, and the thorax was
massaged for 60 s before the BALF was recovered. This
process was repeated once. The recovered lavage samples
were cooled on ice immediately and centrifuged at 150 × g
for 10 min at 4°C. Approximately 4 ml of fluid were recov-
ered from each animal, thus maintaining a roughly equal
amount of BALF among each of the treatment groups.
After centrifugation, the histamine and IL-4 contents in
the BALF were measured using a histamine enzyme im-
munoassay kit (Cayman Chemical, Paris, France) and an
IL-4 ELISA kit (BD Biosciences, NJ, USA), respectively.
Effects of the CTCM on the inhibition of histamine and
IL-4 release in a mast cell culture
P815 cells (mouse lymphoblast-like mastocytoma cell line;
ATCC #TIB-64) were maintained in DMEM medium
supplemented with 10% fetal bovine serum, 100 units/ml
penicillin and 100 μg/ml streptomycin, and incubated at
37°C in the presence of 5% CO2. P815 cells were seeded
in a 96-well plate and treated with serially-diluted concen-
trations of the CTCM or saline for 24 hr. Cytotoxicity
was measured using the 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT)-based in vitro Toxi-
cology Assay Kit (Sigma-Aldrich, St. Louis, MO, USA) to
determine the number of viable cells in proliferation. Cells
were seeded at a density of 5000 cells/well in a 96-well
culture plate. After cells were incubated with various con-
centrations of CTCM, the absorbance was recorded and
analyzed according to the manufacturer's instructions.
The cell numbers were determined using a standard curve
constructed with known numbers of cells.
A total of 106 cells/well of P815 cells were seeded in the
wells of a 24-well cell culture plate. The mast cells were
untreated or pretreated with the CTCM (100 μg/ml) or
cromolyn sodium (a mast cell stabilizer, 10 μg/ml) for
20 min, and then incubated with Compound 48/80 (a mast
cell activator, 10 μg/ml) for 9 hr. The cell culture media
were collected and centrifuged at 150× g for 10 min at 4°C,
and the supernatants were quantified in terms of the levels
of histamine and IL-4 release, as described in the previous
section.
Statistical analysis
Results are expressed as the mean ± SEM. Repeated mea-
sures ANOVA with a Mauchly post-hoc test or One-way
ANOVA with a Duncan post-hoc test were used for
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to indicate significance.Results
The CTCM has a bronchodilating effect
First, we examined the effect of the CTCM on pulmonary
resistance in the guinea pigs. In non-sensitized guinea
pigs, those treated with the nebulized form of CTCM
showed a significantly reduced pulmonary resistance as
compared with the controls, and at 20 min post-CTCM
treatment, the reduction reached a maximum (to 61.0 ±
0.01% of baseline, Figure 1). No change was seen in the
animals treated with saline. This result indicated that the
CTCM has a direct relaxant effect on the airway of the
guinea pig.Figure 1 The CTCM had a bronchodilator effect. Guinea pigs
were treated with a nebulized form of the CTCM, and the pulmonary
resistance (RL) was significantly reduced (to 61.0 ± 0.01% of the baseline)
20 min post-CTCM treatment, while no change was seen in the animals
treated with saline. (A) Overview of the 7-hr period. Comparison
between the NSGP_S and NSGP_M groups. (B) Comparison of the
different groups of sensitized animals in the first hour (repeated
measures ANOVA with a Mauchly post-hoc test; **P <0.01). NSGP_S:
unsensitized guinea pigs treated with saline by nebulization; NSGP_M:
unsensitized guinea pigs treated with 0.06 g/ml CTCM for 5 min
by nebulization.The bronchodilating effect of the CTCM is associated with
the β-adrenoceptor
We previously showed that OVA challenge by nebulization
caused the early antigen response of immediate bron-
choconstriction, which peaked at 15 min in the sensitized
guinea pigs (SGP) and increased the RL by more than 13-
fold that of the control group (unsensitized GP; NSGP)
[28]. When CTCM treatment was administered to the
guinea pigs 5 min before OVA challenge, the OVA-induced
bronchoconstriction was almost completely impeded. In
order to understand the mechanism underlying CTCM
treatment, we investigated whether the β-adrenoceptor is
involved in the bronchodilating effect of the CTCM. As
shown in Figure 2, when OVA-sensitized guinea pigs were
pre-treated with the β-adrenoceptor antagonist propranolol,
the results showed that propranolol attenuated the inhibi-
tory effect of the CTCM. The RL in the SGP_AMO group
was increased to approximately 3–4-fold that of the
SGP_MO group (reaching a maximum at 15 min after chal-
lenge, P <0.01) in the first 30 min (Figure 2). Although the
RL of the SGP_AMO group was increased at 5 and 15 min
and was maintained at a higher level similar to that of the
SGP_O group, the RL was decreased to a similar level to
that of the SGP_MO group 2 hr after challenge. In addition,
no late-phase responses were seen in the SGP_MO and
SGP_AMO groups (Figure 2).Figure 2 The inhibitory effect of the CTCM on OVA-induced RL
increase is mediated by the β-adrenergic receptor.
OVA-sensitized guinea pigs were pre-treated with the β-adrenoceptor
antagonist propranolol, followed by CTCM inhalation or no CTCM
inhalation before OVA challenge. Comparison between the SGP_O,
SGP_MO and SGP_AMO groups of sensitized animals in a 7-hr period
(repeated measures ANOVA with a Mauchly post-hoc test, SGP_AMO
vs. SGP_MO; **P <0.01). Each point represents the mean of the data
from 10-12 animals and the vertical bars represent the standard
deviation. SGP_O: sensitized guinea pigs challenged with OVA by
nebulization; SGP_MO: sensitized guinea pigs treated with 0.06 g/ml
nebulized CTCM for 5 min, followed by OVA challenge by nebulization
(at 5 min post-CTCM nebulization); SGP_AMO: sensitized guinea pigs
pre-treated with β-adrenoceptor antagonist propranolol (1 mg/kg i.v.)
for 3 min before treating with nebulized 0.06 g/ml CTCM for 5 min,
and finally challenged by OVA by nebulization (at 5 min post-CTCM).
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BALF of OVA-challenged guinea pigs
At 5 min after OVA challenge, the histamine level in the
BALF of the control NSGP group was only 4.11 ng/ml;
this increased in the animals of the SGP_O group to
124.04 ng/ml. On the other hand, the histamine level in
the group with CMCT treatment (SGP_MO) was only
16.23 ng/ml, which was close to that in the control group
(NSGP_O) and significantly lower than that in the SGP_O
group (Figure 3A). The IL-4 level in the BALF of the con-
trol group (NSGP_O) was only 30 pg/ml, and increased in
the animals of the SGP_O group to 300 pg/ml. On the
other hand, the IL-4 level in the group with CMCT treat-
ment (SGP_O) was only 100 pg/ml, which was signifi-
cantly lower than that in the SGP_O group (Figure 3B).Figure 3 Effect of the CTCM on the histamine and IL-4 levels in
the BALF. CTCM treatment before OVA challenge reduced the
histamine and IL-4 levels in the BALF 5 min after OVA challenge
(one-way ANOVA with a Duncan post-hoc test, **P <0.01: SGP_MO vs.
SGP_O). Each group represents the mean of the data from 10 animals
and the vertical bars represent the standard deviation. (A) Histamine
and (B) IL-4. NSGP_O: unsensitized guinea pigs challenged with OVA
by nebulization; SGP_O: sensitized guinea pigs challenged with OVA by
nebulization; SGP_MO: sensitized guinea pigs treated with 0.06 g/ml
nebulized CTCM for 5 min, followed by OVA challenge by nebulization
(at 5 min post-CTCM nebulization).The results suggested that mast cells, a major cell type
in the airways, which secrete histamine and IL-4, may
play a role in the OVA-induced airway hypersensitivity,
and CTCM treatment might be able to stop the activa-
tion of mast cells.
The CTCM reduced histamine and IL-4 release in activated
P815 cells
In order to understand how CTCM treatment attenuates
the airway hypersensitivity, we used an in vitro P815 cell
culture to investigate the possible function of mast cells in
this system. P815 cells were treated with the CTCM (1, 10,
100 and 1000 μg/ml) for 24 hr to evaluate the cytotoxicity
of the CTCM towards the cells. MTT assay showed that
P815 cells in the presence of even 1000 μg/ml of the
CTCM did not exhibit significant cytotoxicity, and the cell
viability was greater than 98% (Figure 4). The CTCM at
the lower concentration of 100 μg/ml was then used for
the subsequent experiment.
The baseline value for histamine release in the P815
cells was 0.29 ng/ml. No significant change was seen when
the unactivated P815 cells were treated with CTCM alone.
In the cells activated with Compound 48/80, the histamine
release was increased to 9.06 ng/ml. Interestingly, when
P815 cells were pretreated with the CTCM followed by
Compound 48/80, the results showed a 5-fold decrease in
histamine release. The inhibition ability of the CTCM was
close to that of cromolyn sodium, a mast cell stabilizer
(Figure 5A). On the other hand, Compound 48/80 treat-
ment induced IL-4 release from a baseline of 53.10 pg/ml
to 218.48 pg/ml (Figure 5B). Although the CTCM alone
did not affect IL-4 release in the unactivated cells, CTCMFigure 4 Cytotoxic effect of the CTCM in P815 cells. Various
concentrations of CTCM (1, 10, 100 and 1000 μg/ml) were incubated
with P815 mast cells for 9 hr. The cell viabilities were measured by
MTT assay to determine the percentage of viable cells present. No
significant difference between the CTCM-treated group and the
control was seen (P >0.05).
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48/80-activated mast cells, which was close to the inhib-
ition effect (reduced to (86.24 pg/ml) of cromolyn sodium
pre-treatment (Figure 5B).
The effect of each individual herb was also tested. The re-
sults demonstrated that pre-treatment of cells with Asarum
sieboldii resulted in a significant inhibitive effect on both
IL-4 and histamine release, while Perilla frutescens treat-
ment only had an inhibitive effect on IL-4 release (Figure 6).
No effect was seen in the unactivated cells treated with
the herbs, as well as the Compound 48/80-activated cells
treated with other herbs (data not shown).
Discussion
CTCMs have long been used in a wide range of diseases
in many Asian countries for disease treatment and preven-
tion. As the use of CTCMs is widely accepted by the
people of these countries, the cost of treating diseases is
covered by insurance in most of these countries. It is also
gradually being considered by people in several European
and American countries, especially its use in the treatment
of chronic diseases owing to its effectiveness and the veryFigure 5 Effect of the CTCM on the release of histamine and
IL-4 in P815 mast cells. Compound 48/80 was used to activate the
P815 mast cells as a positive control, and cromolyn sodium was used
to stabilize the mast cells as a negative control. The release of (A)
histamine and (B) IL-4 in the culture medium with saline, “Compound
48/80 (C48/80) + CTCM (100 μg/ml)” or “Compound 48/80 + cromolyn
sodium” were examined (one-way ANOVA with a Duncan post-hoc
test **P <0.01; compared to Compound 48/80 treatment).minor side effects. The increase in the use of CTCMs and
other herbal medicines emphasizes the need to under-
stand the mechanisms of the medicines in order to de-
velop safe and effective therapies.
The present study confirmed our previous findings
that CTCMs administered in nebulized form delivered
through the airways can inhibit OVA-induced airway
hypersensitivity responses in guinea pigs [28], and fur-
ther demonstrated that the effect of a CTCM against
allergic bronchoconstriction acts partly through the β-
adrenergic receptor, at least in the early airway response.
Pre-treatment with propranolol intravenously 3 min be-
fore CTCM inhalation reduced the inhibition effect of
CTCM in the animals during the first 90 min (Figure 2).
No late airway response was seen after 5 hr of OVA
challenge, which suggested that the CTCM had a long-
lasting inhibitory effect on the antigen-induced airway
hypersensitivity. On the other hand, our results demon-
strated that the CTCM used in this study inhibited the
increases in histamine and IL-4 levels in the BALF at
5 min post-OVA challenge. An in vitro experiment using
P815 mouse mast cells revealed that the inhibition effect
of the CTCM was similar to that of a mast cell stabilizer,
cromolyn sodium. In addition, CTCM treatment had no
effect on the basal histamine and IL-4 release in the
unactivated mast cells. Our findings suggest that the
CTCM directly inhibits the secretion of histamine and
IL-4 from activated mast cells, and functions as a mast
cell stabilizer. We observed that degranulation was re-
duced in the cells treated with CTCM; however, we have
not further studied the underlying mechanism, and can-
not conclude that the CTCM has the same targets as
cromolyn sodium. Further studies will be required to
identify the mechanism of the CTCM and investigate
the benefits of the CTCM.
The reduction of IgE in BALF in our previous study [28]
and decrease of histamine levels observed here suggest
that the CTCM is effective in regulating both the early
and late immune response.
Mast cells have been shown to play a key role in asthma
through their release of a variety of mediators, including
histamine, PGD2, tryptase, IL-4 and IL-5 [31]. The release
of histamine from mast cells in the guinea pig is mediated
by β-adrenoceptors [32], and β-adrenoceptor agonists have
been shown to inhibit the anaphylactic release of media-
tors, including histamine, leukotriene C4, D4 and E4 and
thromboxane A2, in an allergic sheep model [33]. Mast cell
activation and the release of stored mediators and cyto-
kines, including histamine and IL-4, are key events in asth-
matic airways [31]. Histamine has been shown to account
for over 50% of allergen-induced early asthmatic reactions
[34,35]. The results of this study showed that the release of
histamine was reduced after OVA challenge in sensitized
guinea pigs pretreated with the CTCM. Our in vitro results
Figure 6 Effects of individual herb treatment on the release of IL-4 and histamine in P815 mast cells. Compound 48/80 (C48/80) was
used to activate the P815 mast cells as a positive control, and cromolyn sodium was used to stabilize the mast cells as a negative control. The
effect of “Individual herb + C48/80” or “cromolyn sodium + C48/80” on the release of (A) IL-4 and (B) histamine in P815 mast cells was examined.
**P <0.01 (compared to Compound 48/80 treatment).
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induced airway reactions through the stabilization of mast
cells in the early-phase reaction after OVA challenge.
Several herbal medicines have been demonstrated to be
effective in the treatment of asthma in animal models and
humans, for example, antiasthma simplified herbal medi-
cine intervention (ASHMI) [25], chai-po-tang (Japanese
name: saiboku-to) [36,37], Ding-Chuan-Tang [21,38],
Houttuynia Cordata [39], Guo-Min-Kang [26], Ma-
Xing-Gan-Shi-Tang [23], San-Ao-Tang [24], and Xiao-
Qing-Long-Tang [22] have all been shown to inhibit
asthmatic responses effectively in animal models and/or
in the treatment of patients. Studies have investigated
the mechanisms of the therapeutic effect of herbal med-
icines in asthma; however, the mechanisms that explain
the beneficial effect of many CTCMs remain unclear. In
this study, we used nebulization and inhalation to admin-
ister the CTCM and investigated the underlying mechan-
ism. Like bronchodilators, the CTCM can be inhaled after
allergen attack, and the increased pulmonary resistance
can be reduced. The inhibition of bronchoconstriction
might occur through several pathways. First, the CTCM
may stabilize mast cells and protect those cells from de-
granulation. Second, it may occur through the inhibition
of released bronchoconstrictors (i.e., histamine). Third, the
CTCM inhibits bronchoconstriction by blocking the re-
ceptors of those bronchoconstrictors, or the stimulation of
β-adrenergic receptors relaxes the airway smooth muscle
and reduces pulmonary resistance.
Ephedrae herba, a known source of ephedrine, has
been used for the treatment of asthma for many years.
A bronchodilatory effect of ephedrine mediated by its
adrenomimetic property has been reported [40]. Although
ephedrine has been reported to inhibit histamine andserotonin release from mast cells in a chemical-induced
anaphylactic animal model [41], in our study no inhib-
ition effect of Ephedrae herba was seen on Compound
48/80-activated P815 cells (data not shown). This could
be due to the ephedrine level in the Ephedrae herba
decoction being much lower than that in the study
that directly used ephedrine. On the other hand, inter-
estingly, our results also revealed that in P815 cells
treated with Asarum sieboldii or Perilla frutescens, IL-4
production from the cells was attenuated, and Asarum
sieboldii had the additional effect of reducing histamine
release. No bronchoconstriction inhibition effect was seen
when the animals inhaled the decoction of the rest of the
individual herbs (data not shown). Asarum sieboldii is
widely used in traditional medicine as it exerts anti-
allergic [42] and anti-inflammatory [43] effects. Recent
study has proved that several active compounds isolated
from Asarum sieboldii have great anti-inflammatory
abilities [44]. Perilla frutescens has also been reported
to have a high antioxidant activity [45]. These two
herbs may contribute majorly to reducing allergic tissue
injury.
In our previous study [28], we demonstrated that the
CTCM has an inhibitory effect on OVA-induced early
and late asthmatic responses; in particular, the CTCM
effectively reduced the serum IgE level, total infiltrated
leukocytes, and IL-5 level in the BALF in the late-phase
reaction to OVA challenge. Several studies have reported
that eosinophils are important in the OVA-induced asth-
matic response of animal models at 1 hr and later time
points [22,46,47]. In the current study, we showed that
mast cells are crucial in the early-phase reaction to OVA
challenge, and CTCM treatment has the important func-
tion of stabilizing mast cells.
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In this study, we showed that the CTCM inhibited his-
tamine and IL-4 secretion by stabilizing mast cells. Our
findings suggested that the CTCM has the effect of a
bronchodilator and exerts an anti-inflammatory effect
in OVA-sensitized guinea pigs, and it can also stabilize
mast cells in terms of the release of histamine and IL-4.
This suggests that this CTCM can be effectively used
for the treatment of asthma via inhalation.
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